EyePoint Pharmaceuticals Q3 revenue falls, net loss widens
EYPT•EyePoint Pharmaceuticals said third-quarter product sales were $528,000 and its net loss widened to $95.61 million. The company plans to cut its workforce by 53%, targeting $30 million in annual savings, and expects topline data from Phase 3 DME trials in early Q4 2027.
1. Quarterly results
EyePoint reported third-quarter product sales of $528,000, a net loss of $95.61 million and operating expenses of $97.63 million. The company said higher expenses were primarily due to ongoing DURAVYU Phase 3 trials for wet age-related macular degeneration and diabetic macular edema.
2. Workforce and outlook
The company plans to reduce its workforce by 53% and focus on its DME program, targeting $30 million in annual savings. EyePoint expects topline data from its Phase 3 DME trials in early Q4 2027 and said operational cash is expected to fund operations into late Q3 2027.
